The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 17, 2020
Filed:
May. 20, 2016
The Broad Institute Inc., Cambridge, MA (US);
Dana-farber Cancer Institute, Inc., Boston, MA (US);
The General Hospital Corporation, Boston, MA (US);
Edward F. Fritsch, Cambridge, MA (US);
Nir Hacohen, Brookline, MA (US);
Michael S. Rooney, Boston, MA (US);
Sachet Ashok Shukla, Natick, MA (US);
Catherine J. Wu, Brookline, MA (US);
Pavan Bachireddy, Boston, MA (US);
Jing Sun, Brookline, MA (US);
The Broad Institute, Inc., Cambridge, MA (US);
Dana Farber Cancer Institute, Inc., Boston, MA (US);
The General Hospital Corporation, Boston, MA (US);
Abstract
Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.